MSB 2.70% 95.0¢ mesoblast limited

Explosive situation, page-18

  1. 349 Posts.
    lightbulb Created with Sketch. 7
    Mesoblast is well advanced in its phase 3 trial for treatment of Crohn's disease and is way ahead of TiGenix which as not commenced a phase 3 trial in the US. Mesoblast is the leader in this field when it comes to Patents and trial time frames completion.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
95.0¢
Change
0.025(2.70%)
Mkt cap ! $1.084B
Open High Low Value Volume
94.0¢ 96.8¢ 93.5¢ $4.207M 4.417M

Buyers (Bids)

No. Vol. Price($)
3 42268 94.0¢
 

Sellers (Offers)

Price($) Vol. No.
95.0¢ 48002 3
View Market Depth
Last trade - 16.10pm 09/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.